| abstract |
Provided herein is an immune cell chimeric antigen receptor comprising (i) an extracellular target binding domain comprising an antibody portion, (ii) a transmembrane domain, and (iii) a primary signaling domain. A chimeric stimulatory receptor (CSR) comprising (CAR), (i) a ligand binding module capable of binding to or interacting with a target ligand, (ii) a transmembrane domain, and (iii) a CD30 co-stimulatory domain. ) and wherein the CSR within the immune cell lacks a functional primary signaling domain. Also provided herein are methods of using it or compositions thereof for the therapeutic treatment of cancer (eg, hematologic cancer or solid tumor cancer). |